ANTIDotE at the International Conference on Lyme Borreliosis and Other Tick-Borne Diseases (ICLB)

The ICLB is a conference focusing on Lyme borreliosis and other tick-borne diseases, where over 250 experienced scientists present and discuss the newest achievements in this field. The ANTIDotE consortium organized a separate session regarding anti-tick vaccines together with the ICLB2018 committee  as part of the ICLB2018 in Atlanta, Georgia, USA. During this session, the ANTIDotE coordinator Prof. dr. Hovius gave an overview of the ANTIDotE project, it's achievements and an outline for future directions. Two members of the ANTIDotE project discussed parts of the scientific work within the project in more details. The anti-tick vaccines session attracted considerable attention and resulted in successful dissemination of the ANTIDotE results and a satisfying intellectual debate with scientific peers.

ICLB2018 program 2

 

ANti-tick vaccines to prevent TIck-borne Diseases in Europe.

EC flag
ANTIDotE
 is a consortium of 7 European research institutes funded by the European Commssion to investigate anti-tick vaccines. Our objective is to identify and characterize tick salivary gland proteins involved in tick feeding and tick-borne pathogen transmission, and to use this knowledge to develop and assess anti-tick vaccines to prevent multiple human tick-borne diseases.

 The Group

The ANTIDotE consortium consists of 7 European participants, and an advisory board with 7 partners with different backgrounds and networks. This enables ANTIDotE to achieve its groundbreaking objectives.

For more information on the participants see the participants section of this website. The advisory board consists of Yale University (Yale), the Research Institite for Wildlife Health in Europe (Artemis), the Friedrich-Loeffler Institute (FLI), the National Institute of Public Health from the Czech Republic (NIPH CZ), Nationa Public Health Institute of Slovenia (NPHI SL), Center for Tick-borne Diseases in Hungary (CTB) and Theo Schetters (current protActivity and former Merck, Sharp & Dohme (MSD).